Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TMO$680.00-26.03(-3.69%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$131.25-0.25(-0.19%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETLRCX$193.00-28.28(-12.78%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ETNVDA$181.99-18.30(-9.14%)Stock Market Today, Nov. 5: Nvidia Slides on AI Chip Selloff as Election Uncertainty Weighs4:49:38 PM ETPTGX$135.26-8.19(-5.71%)Protagonist Therapeutics Q3 revenue surges on Takeda payments4:48:48 PM ETWFC$84.50-2.96(-3.38%)Wells Fargo & Company (WFC) Presents at BancAnalysts Association of Boston Conference 2026 Transcript4:45:03 PM ETTSLA$340.55-44.63(-11.59%)Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms4:43:33 PM ETBAC$49.83-1.81(-3.51%)MEDIA-BofA Rejigs Global Credit Trading Businesses To Boost Liquidity - Bloomberg News4:43:14 PM ETMNKD$3.65-0.29(-7.36%)MannKind Q3 revenue rises on royalty gains4:43:13 PM ETDIS$116.70-2.28(-1.92%)Disney employees use a town hall meeting to press management for details on a possible next round of layoffs4:42:35 PM ETMSFT$530.00-26.01(-4.68%)Microsoft Q3 Earnings: The Only Top AI Hyperscaler Generating Positive FCF (Rating Downgrade)4:42:33 PM ETNVDA$181.99-18.30(-9.14%)Thursday's Final Takeaways: Mortgage Rates Continue Decline, NVDA Chips to China4:34:31 PM ETNVDA$181.99-18.30(-9.14%)Nvidia Plunges 9% as AI Selloff Wipes Out $2.3 Trillion | Closing Bell4:32:42 PM ETKLAC$131.66-17.99(-12.02%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$669.27-126.19(-15.86%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$669.27-126.19(-15.86%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.60-0.28(-0.29%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.08-22.90(-9.50%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$181.99-18.30(-9.14%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$193.00-28.28(-12.78%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$125.24-17.84(-12.47%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$181.99-18.30(-9.14%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$340.55-44.63(-11.59%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ET

SRPT · NASDAQ

Sarepta Therapeutics, Inc.

$17.02 -1.99 (-10.47%)

Company overview

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection for the treatment of Duchenne muscular dystrophy in patients with confirmed mutation of the dystrophin gene amenable to exon 51 skipping, and VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation amenable to exon 53 skipping.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.8B
Employees
1,372
Headquarters
Cambridge, MA
Website
sarepta.com
CEO
Douglas S. Ingram
Listed
June 4, 1997
P/E
27.45
Dividend yield
0.00%

Company financials

Revenue
$2.2B
Gross profit
$1.4B
Operating income
-$41M
EBITDA
$125M
Net income
$65.1M
EPS
$0.62
Total assets
$3.2B
Total debt
$1B
Gross margin
62.39%
Net margin
2.98%
Earnings yield
3.64%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

14.3216.7419.1521.5623.98
SRPT 1D NASDAQ O18.94H19.28L18.52C18.99+0.45 (+2.43%)Vol1.48M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
SRPTSarepta Therapeutics, Inc. Stock news Sarepta Q3 revenue beats estimates Reuters
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments Business Wire
SRPTSarepta Therapeutics, Inc. Press release Astrosalva Therapeutics Adds Rare Disease Patient Advocacy Leader Wendy Erler to Strategic Advisory Board PR Newswire
SRPTSarepta Therapeutics, Inc. Stock news Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy? Zacks Investment Research
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics to Present at Upcoming Investor Conferences Business Wire
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results Business Wire
SRPTSarepta Therapeutics, Inc. Press release Regenerative Medicine Market worth $62.69 billion by 2031 - Exclusive Report by MarketsandMarkets™ PR Newswire
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting Business Wire
SRPTSarepta Therapeutics, Inc. Stock news Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner' Benzinga
SRPTSarepta Therapeutics, Inc. Legal Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT Business Wire
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne Business Wire
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress Business Wire
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting Business Wire
SRPTSarepta Therapeutics, Inc. Stock news Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near MarketBeat
SRPTSarepta Therapeutics, Inc. Stock news Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
SRPTSarepta Therapeutics, Inc. Stock news A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Benzinga
SRPTSarepta Therapeutics, Inc. Stock news Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial Proactive Investors
SRPTSarepta Therapeutics, Inc. Press release Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year Business Wire
SRPTSarepta Therapeutics, Inc. Stock news Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Benzinga
See more
FAQ

Questions about Sarepta Therapeutics, Inc.

What does Sarepta Therapeutics, Inc. do?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection for the treatment of Duchenne muscular dystrophy in patients with confirmed mutation of the dystrophin gene amenable to exon 51 skipping, and VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation amenable to exon 53 skipping.
What is SRPT's market cap?
Sarepta Therapeutics, Inc. (SRPT) is a listed stock with a live quote. The latest market cap on this page is $1.8B.
Where is Sarepta Therapeutics, Inc. headquartered?
Sarepta Therapeutics, Inc. is headquartered in Cambridge, MA.
How do I get SRPT news from the API?
Call GET /v1/news?tickers=SRPT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does SRPT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for SRPT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the SRPT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs